Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Cohen, Stanley; Emery, Paul; Greenwald, Maria; Dougados, Maxime; Furie, Richard; C. Genovese, Mark; Keystone, Edward; Loveless, J.; Burmester, Gerd‐Rüdiger; Cravets, Matthew; Hessey, E.; Shaw, T; C. Totoritis, Mark

doi:10.1002/art.22025

Public

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Published in Arthritis & Rheumatism • Aug 31, 2006

Authors:

Stanley Cohen

Paul Emery

Maria Greenwald

Abstract

OBJECTIVE: To determine the efficacy and safety of treatment with rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapies and to explore the pharmacokinetics and pharmacodynamics of rituxima...

Subject

Medicine

Rituximab

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!